Liver Cancer Screening Market Size, Share and Global Trend By Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma), By Screening (Laboratory Testing, Imaging, Endoscopy, Biopsy), By End User (Hospitals, Oncology Clinics, Diagnostics Centers) and Regional Forecast, 2024-2032

Liver cancer refers to the form or type of cancer that originates in the liver, an organ crucial for the detoxification process and other functions such as metabolism of drugs. The symptoms of liver cancer include weight loss, vomiting, nausea, upper abdominal pain, abdominal swelling, weakness, and fatigue. The exact cause of liver cancer is not clear, but individuals at risk include those with cirrhosis of the liver, chronic infection with hepatitis B or C, certain inherited liver diseases, diabetes, excessive alcohol consumption, and non-alcoholic fatty liver disease.

Several treatment options for liver cancer can be undertaken, such as surgical removal of the tumor, liver transplant surgery, ablative surgery, chemotherapy, radiation therapy, and targeted therapy. Diagnosis of liver cancer is difficult and if diagnosed, is often discovered in its advanced stages, which have the worst prognosis. Cancer screening is surveillance of the body to detect cancer before the development of symptoms to increase the chance of successful treatment.

To gain extensive insights into the market, Request for Customization

The global liver cancer screening market is anticipated to grow, owing to several factors such as increased incidences of liver cancer, demand for advanced treatment options, increased funding for research & development of treatment options, demand for early diagnosis leading, and rising prevalence of liver diseases such as cirrhosis & hepatitis.

According to the American Society for Clinical Oncology (ASCO) in 2018, an estimated 42,220 adults which comprised of 30,610 men and 11,610 women were diagnosed with primary liver cancer in U.S. ASCO also estimated that since 1980, liver cancer rates have tripled, even though diagnosis in young adults see a declining trend. This trend, combined with other factors, is expected to drive the market growth positively.

However, factors limiting the growth of the global liver cancer screening market include lack of awareness about cancer screening. Also, the lack of an advanced molecular diagnostic test for the detection of liver cancer in the low and middle-income countries is expected to hinder the growth of liver cancer screening market during the forecast period.

Key Players Covered

Some of the major companies present in the global liver cancer screening market are Abbott, F. Hoffmann-La Roche Ltd, Illumina, Inc., BIOCEPT, INC., FOUNDATION MEDICINE, INC., Danaher, Sysmex Corporation, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., and Others.

SEGMENTATION 

Among the segmentation of global liver cancer screening market, hepatocellular carcinoma in the type segment accounts for the highest share as it is the most prevalent liver cancer type, and hence will raise the demand for early diagnosis.

Key Insights

• Liver cancer prevalence – for key countries, 2018


• Overview of technological advancements in the liver cancer screening market


• Regulatory scenario – Key countries


• Key mergers and acquisitions

Regional Analysis

Geographically, global liver cancer screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the largest share in the global market due to the increasing prevalence of liver cancer, established healthcare system, high medical expenditure, access to advanced treatment options, demand for preventive care by diagnostic examinations, high demand and research funding for early diagnostic options, and greater awareness of liver cancer. The Asia Pacific is the fastest emerging market owing to the high prevalence of liver cancer, large population pools, rising demand for advanced diagnostics, and expansion of healthcare expenditure due to greater disposable incomes.

Key Industry Developments

• In June 2019, The Johns Hopkins University of Johns Hopkins Health System Corporation, received the largest Series A investment for a Johns Hopkins-licensed technology CANCERSEEK- a liquid biopsy test used to detect multiple cancer types at early stages.


• In July 2018, Epigenomics AG announced the launch of mSEPT9 blood test to aid in detection of liver cancer with higher diagnostic accuracy.


• In May 2018, Oncimmune Holdings plc, announced the launch of EARLYCDT- liver test, a liquid biopsy platform technology for hepatocellular carcinoma (HCC).